AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 1954814
Drug: Omitting morning
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omitting morning short‐acting insulin (hyperglycemic study)
Trial: 27765365
Drug: Oligopin (OP)
RxNorm normalized name: OP-145
DrugBank: OP-145 (DB05672)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oligopin (OP) 75 mg, 2 capsules/day for 5 weeks
Trial: 24997315
Drug: Prior unsuccessful
RxNorm normalized name: Priorix
DrugBank: Rubella virus vaccine (DB10317)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prior unsuccessful eradication treatments
Trial: 16210486
Drug: 7-valent pneumococcal
RxNorm normalized name: Streptococcus pneumoniae serotype 10A capsular antigen diphtheria CRM197 protein conjugate vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-valent pneumococcal conjugate vaccine (PCV), two doses in a 4- to 6-week interval, followed by a booster dose of 23-valent polysaccharide vaccine (PPV) after one year
Trial: 16210486
Drug: 23-valent polysaccharide
RxNorm normalized name: pneumococcal 23-valent polysaccharide vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 23-valent polysaccharide vaccine (PPV), two doses in a 1-year interval
Trial: 9868644
Drug: 400‐mg once‐weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400‐mg once‐weekly fluconazole
Trial: 9868644
Drug: 200‐mg daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200‐mg daily fluconazole
Trial: 7993990
Drug: 750 mg
RxNorm normalized name: bran 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 750 mg pyrantel pamoate tablet formulation
Trial: 7993990
Drug: 750 mg
RxNorm normalized name: bran 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 750 mg pyrantel pamoate suspension formulation
Trial: 7993990
Drug: 750 mg
RxNorm normalized name: bran 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 750 mg pyrantel pamoate other formulation
Trial: 3197751
Drug: Oral ketanserin
RxNorm normalized name: ketanserin
DrugBank: Ketanserin (DB12465)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ketanserin 40 mg b.d. for two months
Trial: 3197751
Drug: Oral ketanserin
RxNorm normalized name: ketanserin
DrugBank: Ketanserin (DB12465)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ketanserin treatment
Trial: 25563311
Drug: BUD plus
RxNorm normalized name: Clove buds
DrugBank: Clove (DB10672)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BUD plus oral MONT (10 μg, qn) for 4 weeks
Trial: 25563311
Drug: Inhaled BUD
RxNorm normalized name: Clove buds
DrugBank: Clove (DB10672)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled BUD (200 μg, bid) for 4 weeks
Trial: 20856190
Drug: Cholinesterase inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholinesterase inhibitors (specific dosage and duration not mentioned)
Trial: 17976988
Drug: Capecitabine 1250
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine 1250 mg/m² orally bid days 1-14
Trial: 17976988
Drug: Vinorelbine 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vinorelbine 30 mg/m² i.v. days 1 and 8
Trial: 12510181
Drug: Electrical acupuncture
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Electrical acupuncture therapy via adhesive surface electrodes and auricular acupuncture therapy
Trial: 8944408
Drug: Chlorpromazine 100
RxNorm normalized name: chlorpromazine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorpromazine 100 mg
Trial: 1629823
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose intravenous methotrexate (MTX) (500 mg/m2) followed by oral leucovorin every 2 weeks for up to 6 months
Trial: 1629823
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose MTX after the high dose protocol
Trial: 9793671
Drug: Cisatracurium, 0.20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisatracurium, 0.20 mg.kg‐1 (4 x ED95)
Trial: 9793671
Drug: Cisatracurium, 0.30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisatracurium, 0.30 mg.kg‐1 (6 x ED95)
Trial: 9793671
Drug: Vecuronium, 0.30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vecuronium, 0.30 mg.kg‐1 (6 x ED95)
Trial: 9793671
Drug: Cisatracurium, 0.40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisatracurium, 0.40 mg.kg‐1 (8 x ED95)
Trial: 336056
Drug: NAB 365
RxNorm normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: NAB 365 (clenbuterol-HCl) 24 micrograms, 3 times daily for 7 days
Trial: 336056
Drug: Fenoterol HBr
RxNorm normalized name: fenoterol hydrobromide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenoterol HBr 5 mg, 3 times daily for 7 days
Trial: 27631775
Drug: Short-course radiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short-course radiotherapy (SC) - 5×5 Gy in 1 week, early surgery, and 6 courses of adjuvant chemotherapy.
Trial: 27631775
Drug: Long-course chemoradiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-course chemoradiotherapy (LC) - 50.4 Gy in 28 fractions over 5.5 weeks with infusion of 5-fluorouracil, surgery in 4 to 6 weeks, and 4 courses of chemotherapy.
Trial: 26437027
Drug: Magnetic sphincter
RxNorm normalized name: MAGNESIA
DrugBank: Magnesium oxide (DB01377)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Magnetic sphincter augmentation device (MSAD)
Trial: 11437028
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of 60 microg PGE1 over 2 hours during pedalergometry
Trial: 9557427
Drug: Thiamine (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiamine (25 mg/day) and Pyridoxine (50 mg/day)
Trial: 9557427
Drug: Thiamine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiamine (1 mg/day) and Pyridoxine (1 mg/day)
Trial: 8345047
Drug: Nal-Glu plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nal-Glu plus T (100 micrograms/kg.day sc plus T enanthate, 200 mg im weekly)
Trial: 8345047
Drug: T alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T alone (placebo sc injections daily plus T enanthate, 200 mg im weekly)
Trial: 3725517
Drug: Monthly booster
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly booster sessions after training
Trial: 27010809
Drug: Ticagrelor (180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticagrelor (180 mg loading dose before PPCI, followed by 90 mg twice daily for 1 year)
Trial: 27010809
Drug: Clopidogrel (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel (600 mg loading dose before PPCI, followed by 75 mg once daily for 1 year)
Trial: 22732382
Drug: Cromolyn sodium
RxNorm normalized name: Cromolyn Sodium
DrugBank: Cromoglicic acid (DB01003)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cromolyn sodium cream 4%
Trial: 15922820
Drug: Nizatidine oral
RxNorm normalized name: nizatidine Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nizatidine oral solution (2.5 mg/kg or 5 mg/kg BID)
Trial: 15922820
Drug: Nizatidine extemporaneous
RxNorm normalized name: Nizatidine
DrugBank: Nizatidine (DB00585)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nizatidine extemporaneous solution (2.5 mg/kg or 5 mg/kg BID)
Trial: 15922820
Drug: Nizatidine capsules
RxNorm normalized name: Nizatidine Capsules
DrugBank: Nizatidine (DB00585)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nizatidine capsules (150 mg BID for ages 13-18)
Trial: 15922820
Drug: Nizatidine (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nizatidine (all formulations)
Trial: 12876092
Drug: Oral or
RxNorm normalized name: Doral Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral or plenary presentation
Trial: 12876092
Drug: Pharmaceutical sponsorship
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pharmaceutical sponsorship
Trial: 1442614
Drug: Low-dose dofetilide
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose dofetilide (3 micrograms/kg loading dose over 15 minutes and 1.5 micrograms/kg maintenance dose over 45 minutes)
Trial: 1442614
Drug: High-dose dofetilide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose dofetilide (6 + 3 micrograms/kg)
Trial: 31680621
Drug: Intramuscular interferon
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular interferon β‐1a
Trial: 30727881
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg non-labeled ACT-541468 with 250 nCi of 14C-labeled ACT-541468
Trial: 17130328
Drug: Hydrocortisone (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocortisone (50 mg x kg(‐1)) before and after cardiopulmonary bypass
Trial: 12480972
Drug: Subcutaneous erythropoietin
RxNorm normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous erythropoietin (Epo) given every 1-3 weeks to maintain hemoglobin at 12.5 g% and intravenous iron (Fe) as necessary.
Trial: 12480972
Drug: Subcutaneous erythropoietin
RxNorm normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous erythropoietin (Epo) and intravenous iron (Fe) treatment.
Trial: 1609038
Drug: Gepirone at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gepirone at a mean dose of 16.25 mg/day
Trial: 3928422
Drug: Intravenous and
RxNorm normalized name: immune globulin intravenous and subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous and intraduodenal amino acid infusion
Trial: 3928422
Drug: Intrajejunal amino
RxNorm normalized name: silk amino acids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrajejunal amino acid infusion
Trial: 31915146
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of physical activity and diet quality
Trial: 31915146
Drug: Physical activity,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical activity, diet quality, and their combination
Trial: 24071616
Drug: PVBs and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PVBs and propofol-based total intravenous anesthesia
Trial: 18621090
Drug: BioDis method
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BioDis method for drug release prediction
Trial: 18621090
Drug: Novel pH-
RxNorm normalized name: PH-284
DrugBank: PH-284 (DB05452)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novel pH- and time-based multi-unit formulations
Trial: 14594516
Drug: Sustained-release oral
RxNorm normalized name: Sustained Release Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release oral morphine (30 mg every 12 h, then titrated)
Trial: 11329100
Drug: 7 days
RxNorm normalized name: ZINGIBER OFFICINALE (GINGER) ROOT OIL 0.006 mg in 30 mg TOPICAL LIQUID [JAYSUING 7 Days Nail Fungus Treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 days of antibiotic therapy (2 days of cefuroxime 750 mg IV every 8 hours followed by 5 days of cefuroxime axetil 500 mg orally every 12 hours)
Trial: 11329100
Drug: 10 days
RxNorm normalized name: AlleRx 10-day Dose Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 days of antibiotic therapy (2 days of cefuroxime 750 mg IV every 8 hours followed by 8 days of cefuroxime axetil 500 mg orally every 12 hours)
Trial: 7772359
Drug: esmolol 1.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: esmolol 1.4 mg/kg
Trial: 2127787
Drug: 1 million
RxNorm normalized name: Nystatin 1 MILLION U Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 million units of interferon alfa-2b, subcutaneously thrice weekly for 6 months
Trial: 2127787
Drug: 3 million
RxNorm normalized name: INTERFERON GAMMA-1B 3 MILLION UNT/0.5ML INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 million units of interferon alfa-2b, subcutaneously thrice weekly for 6 months
Trial: 30388112
Drug: Orally administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally administered lyophilized fecal microbiota product (n = 31)
Trial: 22344198
Drug: Leuprolide acetate
RxNorm normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leuprolide acetate depot 11.25 mg
Trial: 22344198
Drug: Leuprolide acetate
RxNorm normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leuprolide acetate depot 30 mg
Trial: 20640511
Drug: Over-the-counter sales
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Over-the-counter sales of antibiotics
Trial: 20640511
Drug: Injection antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection antibiotics
Trial: 20640511
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of penicillins including β-lactamase inhibitors
Trial: 17998490
Drug: Beta carotene
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta carotene (50 mg, alternate days)
Trial: 12243918
Drug: 3 days
RxNorm normalized name: Transderm Scop 1mg/3 days Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 days of oral amoxicillin
Trial: 12243918
Drug: 5 days
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 days of oral amoxicillin
Trial: 2188379
Drug: Simvastatin 10
RxNorm normalized name: simvastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 10 mg daily
Trial: 31112641
Drug: Midazolam (M;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (M; 6 mg/kg IM)
Trial: 31112641
Drug: Midazolam-butorphanol (MB;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam-butorphanol (MB; 3 mg/kg each IM)
Trial: 26125538
Drug: Armodafinil (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Armodafinil (up to 150 mg/d for 4 weeks)
Trial: 24812897
Drug: Xifeng Zhidong
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Xifeng Zhidong Tablet (XZT)
Trial: 8629589
Drug: Combined alpha-beta
RxNorm normalized name: .alpha.,.beta.'-diglycerin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined alpha-beta blockade (doxazosin 4 mg/day plus metoprolol 6.25 mg, gradually increased to 50 mg twice daily)
Trial: 8629589
Drug: Metoprolol alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol alone (6.25 mg, gradually increased to 50 mg twice daily)
Trial: 2123759
Drug: Pure follicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pure follicle stimulating hormone (FSH)
Trial: 30184513
Drug: Serum 25-hydroxyvitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum 25-hydroxyvitamin D levels <10.0 ng/mL
Trial: 21115795
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg oral torezolid phosphate once daily for 5 to 7 days
Trial: 21115795
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg oral torezolid phosphate once daily for 5 to 7 days
Trial: 21115795
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg oral torezolid phosphate once daily for 5 to 7 days
Trial: 21115795
Drug: Overall (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall (all doses) for patients with S. aureus isolated at baseline
Trial: 21115795
Drug: Overall (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall (all doses) for patients with MRSA isolated at baseline
Trial: 9878937
Drug: Weight-adjusted heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weight-adjusted heparin dosing
Trial: 9878937
Drug: Weight-adjusted heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weight-adjusted heparin dosing and point-of-care monitoring
Trial: 2104626
Drug: Testosterone enanthate
RxNorm normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone enanthate (300 mg/week)
Trial: 2104626
Drug: Placebo (sesame
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (sesame oil, 1 mL)
Trial: 102615
Drug: Oral and
RxNorm normalized name: Tridate, oral and rectal kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral and parenteral antibiotics with extensive bowel preparation in colorectal surgery
Trial: 102615
Drug: Early preoperative
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early preoperative administration of penicillinase-resistant drugs in open fractures (second and third degree lesions)
Trial: 28615379
Drug: Lipid-based nutrient
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid-based nutrient supplements (LNS-PL) containing 250 mug iodine, 20 g/d, 118 kcal
Trial: 28615379
Drug: Iron and
RxNorm normalized name: beef,iron and wine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron and folic acid (IFA; 60 mg Fe/d + 400 mug folic acid/d)
Trial: 26095867
Drug: Bridging therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bridging therapy with low‐molecular‐weight heparin (100 IU of dalteparin per kilogram of body weight) administered subcutaneously twice daily from 3 days before the procedure until 24 hours before the procedure and then for 5 to 10 days after the procedure.
Trial: 26095867
Drug: No bridging
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No bridging therapy (placebo).
Trial: 26095867
Drug: Bridging therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bridging therapy with low‐molecular‐weight heparin (100 IU of dalteparin per kilogram of body weight).
Trial: 11165220
Drug: Temporal covariance
RxNorm normalized name: Sus scrofa temporal lobe preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temporal covariance method using Gd-chelates contrast agent during myocardial perfusion imaging.
Trial: 2643592
Drug: Preoperative hyperthermia
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative hyperthermia (HT) 2 treatments per week
Trial: 2643592
Drug: Preoperative hyperthermia
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative hyperthermia (HT) 1 treatment per week
Trial: 78155
Drug: Probenecid 2
RxNorm normalized name: probenecid 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probenecid 2 g given 30 min before 300 mg of rifampicin
Trial: 78155
Drug: Rifampicin 600
RxNorm normalized name: Rifampicin 600 mg powder for solution for infusion vial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampicin 600 mg standard dose
Trial: 24052026
Drug: Robotic‐assisted gait
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Robotic‐assisted gait training plus conventional physical therapy
Trial: 19929447
Drug: Eletriptan 40
RxNorm normalized name: eletriptan 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eletriptan 40 mg and 80 mg
Trial: 16971319
Drug: Topical 1%
RxNorm normalized name: fluoride topical 1% topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 1% sildenafil applied twice daily for 3 months
Trial: 15374558
Drug: Dolasetron 12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dolasetron 12.5 mg IV
Trial: 15374558
Drug: Dolasetron 50
RxNorm normalized name: dolasetron 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dolasetron 50 mg IV
Trial: 15374558
Drug: Dolasetron (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dolasetron (various doses)
Trial: 11389118
Drug: Oral valaciclovir
RxNorm normalized name: valacyclovir Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral valaciclovir 1000 mg tds
Trial: 11389118
Drug: Intravenous aciclovir
RxNorm normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous aciclovir 5 mg/kg tds
Trial: 8252687
Drug: Intensive therapy
RxNorm normalized name: Cortaid Intensive Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive therapy (colestipol 10 g TID plus niacin 1 g QID or lovastatin 20 mg BID)
Trial: 8252687
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (placebos or colestipol if LDL cholesterol was elevated)
Trial: 12616670
Drug: Delavirdine 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delavirdine 400 mg tid with orange juice
Trial: 12616670
Drug: Delavirdine 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delavirdine 400 mg tid with water
Trial: 2908819
Drug: Atenolol (beta
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (beta 1-selective blocker without agonistic activity)
Trial: 2908819
Drug: Visacor (ICI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Visacor (ICI 141 292) (beta 1-selective blocker with moderate beta 1-selective agonism)
Trial: 2908819
Drug: Corwin (ICI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corwin (ICI 118 587) (beta 1-selective blocker with high beta 1-selective agonism)
Trial: 2908819
Drug: All three
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All three compounds during exercise-induced sympathetic activation
Trial: 28512699
Drug: 60-mg edoxaban
RxNorm normalized name: edoxaban 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60-mg edoxaban tablet crushed and administered via a nasogastric tube